EGFR and neoplasm: This is a novel trial in evaluating the clinical benefits of continuing EGFR inhibition versus VEGF inhibition in treating wild-type KRAS, NRAS and BRAF V600E mCRC tumors with second-line cetuximab or bevacizumab plus chemotherapy crossover after tumor progression to first-line cetuximab regimen.